Case-Control Study: Smoking History Affects the Production of Tumor Antigen–Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease–Free Group

• DOI: 10.1016/j.jtho.2016.09.136
• Publication Date: 2016-10-25T14:15:16Z
• Authors: Dagmar Myšíková; Irena Adkins; Nad'a Hradilová; Ondřej Palata; Jan Šimonek; Jiří Pozniak; Jan Kolařík; Anna Skallová-Fia...; Radek Špíšek; Robert Lischke
• Keywords: Squamous carcinoma

Lung cancer is the leading cause of mortality worldwide; therefore, understanding biological or clinical role tumor-associated antigens and autoantibodies eminent interest for designing antitumor immunotherapeutic strategies.Here we prospectively analyzed serum frequencies New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human epidermal growth factor 2/neu, melanoma-associated antigen A4 (MAGE-A4) antibodies expression corresponding in tumors 121 patients with NSCLC undergoing an operation without prior neoadjuvant chemotherapy compared them those 57 control age-matched no history a malignant disease.We found that only specific NY-ESO-1 (19.8% [n = 24 121]) were significantly increased group controls. seropositivity was positively associated active smoking but not smokers from group. In tumors, frequency mRNA 6.3% (in four 64 patients), 2/neu (HER 2/neu) 11.9% (five 42), MAGE-A4 35.1% (20 57). correlated status male sex NSCLC. Patients displayed higher than did adenocarcinoma. On other hand, 94.7% nonsmoking our study had adenocarcinoma (of whom 73.7% women).These results confirm reported high immunogenicity suggest smoking-induced chronic inflammatory state might potentiate development NY-ESO-1-specific immune responses. Moreover, contribute to cancer/testis such as at early stages development.